Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Squamous Cell Carcinoma

Aliases
Squamous Cell Carcinomas

84 clinical trials

77 products

21 drugs

Product
NM21-1480
Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-06
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2022-10-14
Product
PF-07263689
Product
Sasanlimab
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
SO-C101
Product
DNX-2440
Clinical trial
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis
Status: , Estimated PCD: 2026-07-31
Clinical trial
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer
Status: Active (not recruiting), Estimated PCD: 2020-04-01
Drug
TQB2450
Product
pembrolizumab
Clinical trial
A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MK-3475A in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC.
Status: Recruiting, Estimated PCD: 2027-03-02
Product
MK-3475A
Clinical trial
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-03-06
Product
FT500
Product
Nivolumab
Product
SEA-CD40
Clinical trial
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Status: Completed, Estimated PCD: 2022-11-15
Product
Cemiplimab
Product
Investigator Choice Chemotherapy
Clinical trial
An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Carcinoma
Status: Completed, Estimated PCD: 2021-03-15
Product
Pembrolizumab
Product
Atezolizumab
Product
Fludarabine
Product
IL-2
Product
Cyclophosphamide
Clinical trial
A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Status: Completed, Estimated PCD: 2020-07-29
Clinical trial
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Status:
Product
DKN-01
Product
Gemcitabine
Product
Nab-paclitaxel
Product
L19IL2/L19TNF
Clinical trial
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy
Status: Terminated, Estimated PCD: 2010-10-01
Clinical trial
A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus
Status: Terminated, Estimated PCD: 2015-12-10
Product
Zalutumumab
Product
Selinexor
Product
AVM0703
Clinical trial
AVM0703-EAP
Status:
Product
Hydrocortisone
Product
Proton pump inhibitor
Clinical trial
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2010-12-15
Product
Panitumumab
Clinical trial
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.
Status: Completed, Estimated PCD: 2011-08-01
Product
T3011
Product
T3011 + Pembrolizumab
Clinical trial
A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2023-10-31
Product
Paclitaxel
Clinical trial
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Status: Completed, Estimated PCD: 2019-07-19
Product
Ascorbic acid
Clinical trial
Concentrated Ascorbic Acid in DMSO for Treatment of Squamous Cell Carcinoma of the Skin
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Status: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001
Clinical trial
Open, Prospective Study Evaluating the Efficacy and Safety of 0.05% Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Tirbanibulin
Clinical trial
Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study
Status: Active (not recruiting), Estimated PCD: 2024-04-15
Drug
Liposomal Irinotecan
Drug
Tiragolumab
Clinical trial
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-08-01
Product
DNA Extraction
Clinical trial
Window-of-Opportunity Trial of Nivolumab and BMS986205 in Patients With Squamous Cell Carcinoma of the Head and Neck (CA017-087)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Product
BMS-986205
Clinical trial
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Status: Recruiting, Estimated PCD: 2024-10-23
Product
Aldesleukin
Drug
cyclophosphamide
Product
Young TIL
Clinical trial
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Status: Active (not recruiting), Estimated PCD: 2022-06-01
Product
Mitomycin-C
Product
Pegfilgrastim
Clinical trial
A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers
Status: Recruiting, Estimated PCD: 2027-01-31
Product
Ipilimumab
Product
Prednisone
Drug
sirolimus
Clinical trial
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Drug
Erlotinib
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Clinical trial
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Quercetin
Clinical trial
Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients With Actinic Keratosis - a Double-blind Randomized Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
HPV Vaccine
Product
PLACEBO
Product
Neoantigen Peptide Vaccine
Clinical trial
A Phase II, Multicenter, Single-Arm Clinical Trial of Radiotherapy and CeMiPlimAb: Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Status: Recruiting, Estimated PCD: 2026-10-06
Clinical trial
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx
Status: Withdrawn, Estimated PCD: 2023-07-25
Product
SAR444245
Clinical trial
A Phase II, Open-Label, Single-Arm, Multi-Cohort, Proof-of-Principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors
Status: Completed, Estimated PCD: 2024-04-02
Drug
Atezolizumab
Product
Cobimetinib
Clinical trial
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Afatinib
Clinical trial
Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP
Status: Recruiting, Estimated PCD: 2026-09-01
Product
Chemotherapy TIP
Clinical trial
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Carboplatin
Clinical trial
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2021-09-04
Product
Cetuximab
Clinical trial
A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Rigosertib
Clinical trial
A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design
Status: Recruiting, Estimated PCD: 2030-12-01
Drug
Cisplatin
Drug
Docetaxel
Clinical trial
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.
Status: Recruiting, Estimated PCD: 2024-07-01
Drug
AN0025
Drug
T-VEC
Product
Hydroxyurea
Drug
fluorouracil
Product
Filgrastim
Clinical trial
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Treated With Immune Checkpoint Inhibitors for Various Cancers
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Drug
PD-1 antibody
Clinical trial
Phase I Trial of Radiotherapy in Combination With Atezolizumab in Borderline Resectable and Unresectable Cutaneous Squamous Cell Carcinoma(cSCC)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Study of Talimogene Laherparepvec and Panitumumab in Patients With Locally Advanced Squamous Cell Carcinoma of the Skin (SCCS)
Status: Completed, Estimated PCD: 2023-02-21
Product
Talimogene Laherparepvec
Clinical trial
Investigating the Use of EMLA Topical Cream for Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Cutaneous Cancers
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Eutectic Mixture of Local Anesthetics
Product
Placebo
Clinical trial
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Poly ICLC
Clinical trial
1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
Bavituximab
Drug
mFOLFOX6
Product
Standard of Care PD-1 Therapy
Clinical trial
Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Status: Withdrawn, Estimated PCD: 2026-07-01
Product
Cemiplimab-Rwlc
Product
PEG-IFN alfa-2a
Clinical trial
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
Avelumab
Clinical trial
A Single Arm Phase 2 Study of Talimogene Laherparepvec in Patients With Cutaneous Squamous Cell Cancer
Status: Completed, Estimated PCD: 2023-07-19
Product
TVEC Injection
Product
TVEC injection
Product
TVEC
Clinical trial
A Phase 1B Study of Intralesional Injection of RP1 in Patients With Resectable Cutaneous SCC
Status: Recruiting, Estimated PCD: 2025-12-01
Drug
RP1
Clinical trial
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-04-05
Clinical trial
The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer
Status: Active (not recruiting), Estimated PCD: 2020-04-01
Clinical trial
A Single and Repeat Dosing and Expansion Study of the Safety, Drug Exposure and Clinical Activity of R-5780 in Combination With a PD-1 (Checkpoint Protein on Immune Cells Called T Cells) Pathway Checkpoint Inhibitor in Patients With Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Product
R-5780
Clinical trial
Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-07-05
Product
IRX-2
Clinical trial
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Status: Active (not recruiting), Estimated PCD: 2022-09-20
Drug
Varlilumab
Clinical trial
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
Status: Completed, Estimated PCD: 2005-01-01
Clinical trial
Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study
Status: Recruiting, Estimated PCD: 2024-06-17
Product
OBP-301
Clinical trial
Chemo-embolization for Head and Neck Cancer
Status: Not yet recruiting, Estimated PCD: 2028-01-01
Clinical trial
MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas
Status: Terminated, Estimated PCD: 2023-05-23
Product
Imvamune
Clinical trial
Immune Checkpoint Blockade for Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
Status: Active (not recruiting), Estimated PCD: 2022-10-11
Drug
Lurbinectedin
Clinical trial
A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001
Status: Recruiting, Estimated PCD: 2025-12-01
Product
BMX-001
Clinical trial
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Drug
R-CHOP
Clinical trial
EACH: A Randomised Phase II Study Evaluating the Safety and Anti-tumour Activity of the Combination of Avelumab and Cetuximab Relative to Avelumab Monotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2021-09-15
Clinical trial
Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Active (not recruiting), Estimated PCD: 2020-09-29
Clinical trial
The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to Evaluate the Safety, Determine Recommended Phase 2 Dose (RP2D), and Investigate the Biologic and Clinical Activity
Status: Completed, Estimated PCD: 2021-02-21
Product
IRX 2
Clinical trial
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-02-27
Clinical trial
A Window of Opportunity Trial of Cetuximab in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Completed, Estimated PCD: 2022-03-15
Clinical trial
Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer
Status: Completed, Estimated PCD: 2012-10-01
Clinical trial
A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-07
Product
Copaxone
Clinical trial
Concurrent Nab--paclitaxel/Carboplatin and Thoracic Radiotherapy in Inoperable Stage III Squamous Cell Lung Cancer
Status: Terminated, Estimated PCD: 2021-12-12
Drug
Abraxane
Clinical trial
Combination Topical 5-fluorouracil 5% / Calcipotriene 0.005% Cream for Treatment of in Situ and Superficially Invasive Squamous Cell Carcinoma of the Skin
Status: Recruiting, Estimated PCD: 2023-12-01
Product
Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream
Product
Nourivan
Clinical trial
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW)
Status: Completed, Estimated PCD: 2020-02-18
Drug
Sitravatinib
Clinical trial
Phase II Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Status: Active (not recruiting), Estimated PCD: 2024-04-12
Clinical trial
Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study
Status: Not yet recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Pilot Study of Induction Therapy Followed by Response-adaptive Treatment and Dynamic Changes in Circulating Tumor DNA in Locoregionally Advanced HPV Negative Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-01
Drug
cetuximab
Product
TFHX Regimen
Clinical trial
Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2030-10-01
Clinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line
Status: Completed, Estimated PCD: 2023-01-01
Product
Keytruda